Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 4/20 | 0.64 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.56 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL13737971 | 0.96 | ESR2 (0.60) | ESR2SRD5A1HTR3ASLC2A1ALDH1A1 | |
| SCHEMBL28137635 | 0.92 | ESR2 (0.69) | ESR2SRD5A1HTR3ASLC2A1ALDH1A1 | |
| SCHEMBL14403055 | 0.89 | ESR2 (0.78) | ESR2SRD5A1POLBKMT2AMAPT | |
| SCHEMBL8038498 | 0.88 | ESR2 (0.52) | ESR2SRD5A1HTR3ASLC2A1ALDH1A1 | |
| SCHEMBL8038502 | 0.88 | ESR2 (0.52) | ESR2SRD5A1HTR3ASLC2A1ALDH1A1 | |
| SCHEMBL444141 | 0.88 | SRD5A1 (0.53) | ESR2SRD5A1HTR3ASLC2A1ALDH1A1 | |
| Tetrahydrofuran SCHEMBL28842388 | 0.88 | ESR2 (0.51) | ESR2SRD5A1HTR3ASLC2A1ALDH1A1 | |
| SCHEMBL8518348 | 0.84 | ESR2 (0.47) | ESR2SRD5A1HTR3ASLC2A1ALDH1A1 | |
| SCHEMBL8518350 | 0.84 | ESR2 (0.47) | ESR2SRD5A1HTR3ASLC2A1ALDH1A1 | |
| SCHEMBL10348022 | 0.82 | ESR2 (0.69) | ESR2SRD5A1ALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106496005-B | Synthesis method of 4- (4-chlorphenyl) cyclohexanone | 上海毕得医药科技有限公司 | 2019-04-09 | — | — | CN | claimed |
| CN-106496008-A | Method for synthesizing 4- (4-chlorphenyl) cyclohexanone | 上海毕得医药科技有限公司 | 2017-03-15 | — | — | CN | claimed |
| WO-2012153162-A1 | NOVEL METHOD FOR PREPARATION OF ATOVAQUONE | LUPIN LIMITED (IN) | 2012-11-15 | — | — | WO | claimed |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4705298-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | MOMA THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024211836-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| CN-115433186-A | 4, 5-dihydro-3H-pyrrolo [2,3-c ] quinoline compound and synthetic method thereof | 湘潭大学 | 2022-12-06 | — | — | CN | disclosed |
| US-6600015-B2 | Treatment or prevention of obesity. | HOFFMANN-LA ROCHE INC. | 2003-07-29 | — | — | US | disclosed |
| EP-1315750-A2 | CYCLIC PEPTIDES HAVING MELANOCORTIN-4 RECEPTOR AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| EP-1272516-A2 | SELECTIVE LINEAR PEPTIDES WITH MELANOCORTIN-4 RECEPTOR (MC4-R) AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-08 | — | — | EP | disclosed |
| WO-2003000676-A1 | 1,2,4-TRIOXOLANE ANTIMALARIALS | MEDICINES FOR MALARIA VENTURE (CH) | 2003-01-03 | — | — | WO | disclosed |
| US-6486199-B1 | Spiro and dispiro 1,2,4-trioxolane antimalarials | MEDICINES FOR MALARIA VENTURE MMV INTERNATIONAL CENTRE COINTRIN (CH) | 2002-11-26 | — | — | US | disclosed |
| US-20020143141-A1 | Selective cyclic peptides with melanocortin-4 receptor (MC4-R) agonist activity | CHEN LI (US) | 2002-10-03 | — | — | US | disclosed |
| WO-2002018437-A2 | CYCLIC PEPTIDES HAVING MELANOCORTIN-4 RECEPTOR AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
| US-20010056179-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | HOFFMANN-LA ROCHE INC. | 2001-12-27 | — | — | US | disclosed |
| WO-2001074844-A2 | SELECTIVE LINEAR PEPTIDES WITH MELANOCORTIN-4 RECEPTOR (MC4-R) AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143141-A1 | Selective cyclic peptides with melanocortin-4 receptor (MC4-R) agonist activity | MC4R, MC3R, MC1R | ESR2 1272/4885SRD5A1 2431/4885HTR3A 438/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | ESR2 90/4885SRD5A1 394/4885HTR3A 1734/4885 |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLQ, POLB, POLK | ESR2 1652/4885SRD5A1 440/4885HTR3A 3327/4885 |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLA1, SUB1, CTDSP1 | ESR2 3523/4885SRD5A1 105/4885HTR3A 2425/4885 |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | POLA1, CTDSP1, SUB1 | ESR2 2976/4885SRD5A1 150/4885HTR3A 3028/4885 |
| US-20010056179-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | MC4R, MC3R, MC1R | ESR2 1169/4885SRD5A1 3064/4885HTR3A 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.